Actuate receives a favorable FDA Written Response to our Pre-IND Plan for the development of 9-ING-41. The FDA laid out a very clear path on tasks necessary to complete in order to submit an IND, which sets the company up well for advancing 9-ING-41 into the clinic, and ultimately, to effectively treating patients.